Emeren Group’s Resilience and Strategic Shifts Support Buy Rating Amid Promising Growth Outlook
Analyst Amit Dayal of H.C. Wainwright maintained a Buy rating on Emeren Group (SOL – Research Report), retaining the price target of ...
Optimistic Buy Rating for Galectin Therapeutics: Strategic Trial Design and Financial Stability Boost Prospects
Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on Galectin Therapeutics (GALT – Research Report) and keeping the price ...